AR054320A1 - Derivados de piridinilo y pirimidinilo sustituidos como moduladores del metabolismo y para tratar trastornos metabolicos. composiciones farmaceuticas - Google Patents
Derivados de piridinilo y pirimidinilo sustituidos como moduladores del metabolismo y para tratar trastornos metabolicos. composiciones farmaceuticasInfo
- Publication number
- AR054320A1 AR054320A1 ARP060100071A ARP060100071A AR054320A1 AR 054320 A1 AR054320 A1 AR 054320A1 AR P060100071 A ARP060100071 A AR P060100071A AR P060100071 A ARP060100071 A AR P060100071A AR 054320 A1 AR054320 A1 AR 054320A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkoxy
- alkyl
- group
- pharmaceutical compositions
- piridinyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Composiciones farmacéuticas que comprenden dichos compuestos. Reivindicacion 1: Un compuesto de formula (1), o una de sus sales farmacéuticamente aceptables, sus solvatos o hidratos; en donde: X es N o CR8 en donde R8 es H o halogeno; Y es NH u O; Z es CH o N; R1 es carbo-alcoxiloC1-4, oxadiazolilo o pirimidinilo en donde cada carbo-alcoxiloC1-6, oxadiazolilo y pirimidinilo está opcionalmente sustituido con 1 o 2 sustituyentes seleccionados independientemente del grupo integrado por alquilo C1-4, alcoxilo C1-4 y cicloalquilo C3-5; R2 es H alquilo C1-4; R3 es alcoxilo C1-4, O-alquiniloC2-4 o hidroxilo; R4 se selecciona del grupo integrado por H, alcoxilo C1-4, alquilo C1-4, alquinilo C2-4 y halogeno; R5 se selecciona del grupo integrado por acilsulfonamida C1-4, alcoxilo C1-4, alquilo C1-4, alquilamino C1-4, alquilsulfonilo C1-4, alquiltio C1-4, ciano, heterociclilo di-dialquilaminoC1-4 y sulfonamida, en donde cada alcoxilo C1-4, alquilo C1-4, alquilamino C1-4, alquilsulfonilo C1- 4, alquiltio C1-4, di-dialquilaminoC1-4 y heterociclilo está opcionalmente sustituido con 1 o 2 sustituyentes seleccionados independientemente del grupo integrado por alquinilo C2-4, alcoxilo C1-4, alquilcarboxamida C1-4, alquilsulfonilo C1-4, cicloalquilo C3-5, cicloalquiloxilo C3-5, di-alquilcarboxamidaC1-4, hidroxilo y fosfonooxilo, en donde dicha alquilcarboxamida C1-4 está opcionalmente sustituida con hidroxilo; o R5 es un grupo de formula (2), en donde ômö, ônö y ôqö son independientemente 0, 1, 2 o 3; ôrö es 0, 1 'p 2; y ôtö es 0 o 1; R6 es H o halogeno; y R7 es H alquilo C1-4.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64284005P | 2005-01-10 | 2005-01-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR054320A1 true AR054320A1 (es) | 2007-06-20 |
Family
ID=36755755
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060100071A AR054320A1 (es) | 2005-01-10 | 2006-01-09 | Derivados de piridinilo y pirimidinilo sustituidos como moduladores del metabolismo y para tratar trastornos metabolicos. composiciones farmaceuticas |
Country Status (37)
| Country | Link |
|---|---|
| US (3) | US20060155128A1 (es) |
| EP (2) | EP1732562B1 (es) |
| JP (1) | JP2008526882A (es) |
| KR (1) | KR20070098907A (es) |
| CN (2) | CN102125555A (es) |
| AR (1) | AR054320A1 (es) |
| AT (2) | ATE381558T1 (es) |
| AU (1) | AU2006211583C1 (es) |
| BR (1) | BRPI0606704A (es) |
| CA (1) | CA2594466A1 (es) |
| CR (1) | CR9225A (es) |
| CY (2) | CY1107215T1 (es) |
| DE (2) | DE602006009946D1 (es) |
| DK (2) | DK1732562T3 (es) |
| EA (1) | EA015714B1 (es) |
| ES (2) | ES2333824T4 (es) |
| GE (1) | GEP20094828B (es) |
| GT (1) | GT200600006A (es) |
| HK (2) | HK1094542A1 (es) |
| HN (2) | HN2006000969A (es) |
| HR (2) | HRP20080113T3 (es) |
| IL (1) | IL184363A0 (es) |
| MX (1) | MX2007008402A (es) |
| MY (1) | MY148521A (es) |
| NI (1) | NI200700169A (es) |
| NO (1) | NO20073806L (es) |
| NZ (1) | NZ556220A (es) |
| PE (2) | PE20060857A1 (es) |
| PL (2) | PL1732562T3 (es) |
| PT (2) | PT1732562E (es) |
| RS (2) | RS50540B (es) |
| SG (1) | SG158875A1 (es) |
| SI (2) | SI1732562T1 (es) |
| TW (1) | TW200637845A (es) |
| UA (1) | UA89812C2 (es) |
| WO (1) | WO2006083491A2 (es) |
| ZA (1) | ZA200705471B (es) |
Families Citing this family (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| BRPI0406761A (pt) | 2003-01-14 | 2005-12-20 | Arena Pharm Inc | Derivados de arila e heteroarila 1,2,3-trissubstituìdos como moduladores do metabolismo e a profilaxia e tratamento de distúrbios relacionados a estes tais como diabetes e hiper-glicemia |
| PL378295A1 (pl) * | 2003-02-24 | 2006-03-20 | Arena Pharmaceuticals, Inc. | Podstawione pochodne arylowe i heteroarylowe jako modulatory metabolizmu glukozy oraz profilaktyka i leczenie zaburzeń tego metabolizmu |
| US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
| CN1997640A (zh) * | 2004-06-04 | 2007-07-11 | 艾尼纳制药公司 | 作为代谢调节剂的经取代芳基和杂芳基衍生物及其相关病症的预防和治疗 |
| DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
| MY148521A (en) * | 2005-01-10 | 2013-04-30 | Arena Pharm Inc | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto |
| DOP2006000010A (es) | 2005-01-10 | 2006-07-31 | Arena Pharm Inc | Procedimiento para preparar eteres aromáticos |
| DOP2006000008A (es) * | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
| CA2610196A1 (en) * | 2005-06-09 | 2006-12-14 | Merck Frosst Canada Ltd. | Azacyclohexane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| MX2007015867A (es) * | 2005-06-14 | 2008-03-04 | Hoffmann La Roche | Derivados del acido antranilico. |
| DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| NZ565898A (en) * | 2005-09-16 | 2010-07-30 | Arena Pharm Inc | Modulators of metabolism and the treatment of disorders related thereto |
| ES2354390T3 (es) * | 2006-04-11 | 2011-03-14 | Arena Pharmaceuticals, Inc. | Procedimientos de uso del receptor gpr119 para identificar compuestos útiles para aumentar la masa ósea en un individuo. |
| PE20071221A1 (es) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
| EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| CN109503584A (zh) | 2006-05-04 | 2019-03-22 | 勃林格殷格翰国际有限公司 | 多晶型 |
| TW200811147A (en) * | 2006-07-06 | 2008-03-01 | Arena Pharm Inc | Modulators of metabolism and the treatment of disorders related thereto |
| TW200811140A (en) * | 2006-07-06 | 2008-03-01 | Arena Pharm Inc | Modulators of metabolism and the treatment of disorders related thereto |
| US7638541B2 (en) | 2006-12-28 | 2009-12-29 | Metabolex Inc. | 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
| CN101668759A (zh) * | 2007-05-04 | 2010-03-10 | 百时美施贵宝公司 | [6,5]-双环gpr119g蛋白-偶合受体激动剂 |
| WO2008137435A1 (en) * | 2007-05-04 | 2008-11-13 | Bristol-Myers Squibb Company | [6,6] and [6,7]-bicyclic gpr119 g protein-coupled receptor agonists |
| EA016595B1 (ru) | 2007-07-17 | 2012-06-29 | Бристол-Маерс Сквибб Компани | Способ модулирования рецептора gpr119, сопряженного с g-белком, и используемые при этом соединения |
| AU2008279447A1 (en) * | 2007-07-19 | 2009-01-29 | Metabolex, Inc. | N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| WO2009038974A1 (en) * | 2007-09-20 | 2009-03-26 | Irm Llc | Compounds and compositions as modulators of gpr119 activity |
| US8232287B2 (en) * | 2007-10-16 | 2012-07-31 | Daiichi Sankyo Company, Limited | Pyrimidyl indoline compound |
| JP2011500727A (ja) * | 2007-10-22 | 2011-01-06 | シェーリング コーポレイション | Ｇｐｒ１１９の活性のモジュレーターとしての二環式ヘテロ環誘導体およびその使用 |
| CA2716755A1 (en) * | 2008-02-29 | 2009-09-03 | Peter C. Chua | Protein kinase modulators |
| PE20091730A1 (es) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
| EP2146210A1 (en) * | 2008-04-07 | 2010-01-20 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY |
| JP2011524917A (ja) * | 2008-06-20 | 2011-09-08 | メタボレックス， インコーポレイテッド | アリールｇｐｒ１１９作動薬およびその使用 |
| TW201006821A (en) * | 2008-07-16 | 2010-02-16 | Bristol Myers Squibb Co | Pyridone and pyridazone analogues as GPR119 modulators |
| BRPI0916997A2 (pt) | 2008-08-06 | 2020-12-15 | Boehringer Ingelheim International Gmbh | Inibidor de dpp-4 e seu uso |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| MX2011002558A (es) | 2008-09-10 | 2011-04-26 | Boehringer Ingelheim Int | Terapia de combinacion para el tratamiento de diabetes y estados relacionados. |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| US20100113480A1 (en) * | 2008-10-30 | 2010-05-06 | Michael Reuman | Process for the preparation of tri-substituted pyridine and tri-substituted pyrimidine derivatives useful as gdir agonists |
| US20100113479A1 (en) * | 2008-10-30 | 2010-05-06 | Anusuya Choudhury | Process for the preparation of tri-substituted pyridine and tri-substituted pyrimidine derivatives useful as gdir agonists |
| US20110160222A1 (en) * | 2008-11-26 | 2011-06-30 | Metabolex, Inc. | Modulators of glucose homeostasis for the treatment of diabetes and metabolic disorders |
| WO2010075269A1 (en) * | 2008-12-23 | 2010-07-01 | Schering Corporation | Pyrimidine derivatives as gpcr modttlators for use in the treatment of obesity and diabetes |
| JP2012513470A (ja) | 2008-12-23 | 2012-06-14 | シェーリング コーポレイション | 二環式複素環誘導体及びその使用方法 |
| EA022310B1 (ru) | 2008-12-23 | 2015-12-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Солевые формы органического соединения |
| AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
| US8410089B2 (en) | 2009-02-18 | 2013-04-02 | Takeda Pharmaceutical Company Limited | Fused heterocyclic ring compound |
| TW201039827A (en) * | 2009-04-15 | 2010-11-16 | Daiichi Sankyo Co Ltd | Indoline compound |
| US20100298362A1 (en) * | 2009-05-20 | 2010-11-25 | Xun Li | Process for the preparation of 4-[6-(6-methanesulfonyl-2-methyl-pyridin-3-ylamino)-5-methoxy-pyrimidin-4-yloxy]-piperidine-1-carboxylic acid isopropyl ester |
| US20110015215A1 (en) * | 2009-05-20 | 2011-01-20 | Paul Deghetto | Crystalline forms of 4-[6-(6-methanesulfonyl-2-methyl-pyridin-3-ylamino)-5-methoxy-pyrimidin-4-yloxy]-piperidine-1-carboxylic acid isopropyl ester |
| TW201111361A (en) | 2009-06-24 | 2011-04-01 | Boehringer Ingelheim Int | New compounds, pharmaceutical composition and methods relating thereto |
| JP2012530758A (ja) | 2009-06-24 | 2012-12-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規化合物、医薬組成物及びそれに関する方法 |
| ES2497566T3 (es) | 2009-10-01 | 2014-09-23 | Cymabay Therapeutics, Inc. | Sales de tetrazol-1-il-fenoximetil-tiazol-2-il-piperidinil-pirimidina sustituida |
| MX364651B (es) | 2009-11-27 | 2019-05-03 | Boehringer Ingelheim Int Gmbh Star | Inhibidores de dpp-iv, tales como la linagliptina, y composiciones farmacéuticas o combinaciones que comprenden los mismos, para usarse en el tratamiento de pacientes diabéticos tipificados genéticamente. |
| EP4148045A1 (en) | 2010-01-27 | 2023-03-15 | Arena Pharmaceuticals, Inc. | Intermediate compounds for the preparation of (r)-2-(7-(4-cyclopentyl-3- (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b] indol-3-yl)acetic acid and salts thereof |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2547339A1 (en) | 2010-03-18 | 2013-01-23 | Boehringer Ingelheim International GmbH | Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions |
| JP2013523822A (ja) | 2010-04-08 | 2013-06-17 | ブリストル−マイヤーズ スクイブ カンパニー | Ｇｐｒ１１９修飾因子としてのピリミジニルピペリジニルオキシピリジノ類似体 |
| EP2566469B1 (en) | 2010-05-05 | 2022-12-21 | Boehringer Ingelheim International GmbH | Combination therapy |
| WO2011140160A1 (en) | 2010-05-06 | 2011-11-10 | Bristol-Myers Squibb Company | Bicyclic heteroaryl compounds as gpr119 modulators |
| WO2011140161A1 (en) | 2010-05-06 | 2011-11-10 | Bristol-Myers Squibb Company | Benzofuranyl analogues as gpr119 modulators |
| US8933024B2 (en) | 2010-06-18 | 2015-01-13 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| CA2802541A1 (en) | 2010-06-23 | 2011-12-29 | Metabolex, Inc. | Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
| EA201991014A1 (ru) | 2010-06-24 | 2019-09-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Лечение диабета |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| WO2012025811A1 (en) | 2010-08-23 | 2012-03-01 | Lupin Limited | Indolylpyrimidines as modulators of gpr119 |
| CN103189360A (zh) | 2010-09-01 | 2013-07-03 | 艾尼纳制药公司 | 5-ht2c激动剂的非吸湿性盐 |
| MX2013002422A (es) | 2010-09-01 | 2013-05-17 | Arena Pharm Inc | Sales de lorcaserina con acidos opticamente activos. |
| EP3485878A1 (en) | 2010-09-01 | 2019-05-22 | Arena Pharmaceuticals, Inc. | Modified-release dosage forms of 5-ht2c agonists useful for weight management |
| CA2808900A1 (en) | 2010-09-01 | 2012-03-08 | Arena Pharmaceuticals, Inc. | Fast-dissolve dosage forms of 5-ht2c agonists |
| AU2011305525B2 (en) | 2010-09-22 | 2016-08-18 | Arena Pharmaceuticals, Inc. | Modulators of the GPR119 receptor and the treatment of disorders related thereto |
| KR101563793B1 (ko) * | 2010-10-08 | 2015-10-27 | 카딜라 핼쓰캐어 리미티드 | 신규한 ｇｐｒ 119 작용물질 |
| AR083878A1 (es) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
| AU2011333472A1 (en) | 2010-11-26 | 2013-06-06 | Lupin Limited | Bicyclic GPR119 modulators |
| WO2012093809A2 (en) * | 2011-01-03 | 2012-07-12 | Hanmi Pharm Co., Ltd. | New bicyclic compound for modulating g protein-coupled receptors |
| US20140038889A1 (en) * | 2011-04-22 | 2014-02-06 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
| EP2718279B1 (en) | 2011-06-09 | 2016-08-10 | Rhizen Pharmaceuticals SA | Novel compounds as modulators of gpr-119 |
| US8883800B2 (en) | 2011-07-15 | 2014-11-11 | Boehringer Ingelheim International Gmbh | Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| WO2013171167A1 (en) | 2012-05-14 | 2013-11-21 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome |
| US9174965B2 (en) | 2012-05-16 | 2015-11-03 | Bristol-Myers Squibb Company | Pyrimidinylpiperidinyloxypyridone analogues as GPR119 modulators |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| JP6430480B2 (ja) * | 2013-03-15 | 2018-11-28 | ナイキ イノベイト セー． フェー． | ビロー構造を含有するソール構造を含むフットウェア製品 |
| WO2015128453A1 (en) | 2014-02-28 | 2015-09-03 | Boehringer Ingelheim International Gmbh | Medical use of a dpp-4 inhibitor |
| AU2016205361C1 (en) | 2015-01-06 | 2021-04-08 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the S1P1 receptor |
| IL285890B (en) | 2015-06-22 | 2022-07-01 | Arena Pharm Inc | Slate-free crystal of the arginine salt of (Ar)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-4,3,2,1-tetrahydro-cyclopent[b]indole-3-yl ) acetic acid |
| WO2017211979A1 (en) | 2016-06-10 | 2017-12-14 | Boehringer Ingelheim International Gmbh | Combinations of linagliptin and metformin |
| EP3493807A1 (en) | 2016-08-03 | 2019-06-12 | CymaBay Therapeutics, Inc. | Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions |
| US11077108B2 (en) | 2016-09-07 | 2021-08-03 | The Regents Of The University Of California | Allosteric corticotropin-releasing factor receptor 1 (CRFR1) antagonists that decrease p-tau and improve cognition |
| US11534424B2 (en) | 2017-02-16 | 2022-12-27 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of primary biliary cholangitis |
| WO2018236896A1 (en) | 2017-06-19 | 2018-12-27 | Arena Pharmaceuticals, Inc. | COMPOUNDS AND METHODS FOR THE TREATMENT OF NAFLD AND NASH |
| CN108658871B (zh) * | 2018-06-19 | 2020-10-30 | 舞阳威森生物医药有限公司 | 周效磺胺中间体4,6-二氯-5-甲氧基嘧啶的制备方法 |
| CN108892635A (zh) * | 2018-09-07 | 2018-11-27 | 江苏工程职业技术学院 | 一种西沙必利关键中间体的制备方法 |
Family Cites Families (139)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US427174A (en) * | 1890-05-06 | Minor c | ||
| US618777A (en) * | 1899-01-31 | Window | ||
| CH389134A (de) | 1960-03-15 | 1965-03-15 | Ciba Geigy | Verfahren zur Herstellung neuer Anthrachinonküpenfarbstoffe |
| CH499528A (de) | 1965-10-22 | 1970-11-30 | Ciba Geigy Ag | Verfahren zur Herstellung neuer Pyrimidine |
| CH480410A (de) | 1967-01-09 | 1969-10-31 | Geigy Ag J R | Verfahren zur Herstellung von wasserlöslichen Azopyrimidinfarbstoffen |
| CA961052A (en) | 1967-01-12 | 1975-01-14 | Max Schellenbaum | N-2-ethylhexyl-n'-aryl ureas and preparation containing them |
| FR1593586A (es) | 1967-10-17 | 1970-06-01 | ||
| US3608087A (en) | 1968-06-21 | 1971-09-21 | Merck & Co Inc | Feed compositions |
| US3887329A (en) | 1969-05-05 | 1975-06-03 | Ciba Geigy Ag | Hexamethyl phosphotriamide-dye compositions |
| BE756953A (fr) | 1969-10-02 | 1971-04-01 | Merck & Co Inc | Potentialisation d'antibiotiques |
| US3686238A (en) | 1970-01-19 | 1972-08-22 | Syntex Corp | Glycerol esterified with 2-naphthyl-acetic acids and fatty acids |
| US3852434A (en) | 1970-09-11 | 1974-12-03 | Merck & Co Inc | Potentiation of ({31 ) cis-1,2-epoxypropyl)phosphonic acid and analogues thereof |
| US3966744A (en) | 1971-01-11 | 1976-06-29 | Syva Company | Spin labeled compounds |
| US3690834A (en) | 1971-01-11 | 1972-09-12 | Syva Co | Ligand determination with spin labeled compounds by receptor displacement |
| DE2106585A1 (de) | 1971-02-11 | 1972-08-24 | Farbenfabriken Bayer Ag, 5090 Leverkusen | Aminothiodiazole und Thiodiazol-Azofarbstoffe |
| CH558137A (de) | 1971-05-17 | 1975-01-31 | Ciba Geigy Ag | Mittel zur beeinflussung des pflanzenwachstums. |
| CH560197A5 (en) | 1971-05-17 | 1975-03-27 | Ciba Geigy Ag | 2-alkylthio-4,6-bis (subst amino)-5-nitropyrimidines - - herbicides |
| US3966764A (en) | 1972-07-10 | 1976-06-29 | Syva Company | Ligand determination of spin labeled compounds by receptor displacement-amphetamine analogs |
| US3849420A (en) | 1972-10-20 | 1974-11-19 | Dow Chemical Co | Bis-(alkylthio-and alkylsulfonyl)-pentachloroquinolines |
| CH574206A5 (es) * | 1972-11-16 | 1976-04-15 | Ciba Geigy Ag | |
| DE2340569C2 (de) | 1973-08-10 | 1982-12-02 | Bayer Ag, 5090 Leverkusen | Azofarbstoffe |
| AT340933B (de) | 1973-08-20 | 1978-01-10 | Thomae Gmbh Dr K | Verfahren zur herstellung neuer pyrimidinderivate und ihrer saureadditionssalze |
| DE2341925A1 (de) | 1973-08-20 | 1975-03-06 | Thomae Gmbh Dr K | Neue pyrimidinderivate und verfahren zu ihrer herstellung |
| CH584739A5 (es) | 1973-12-21 | 1977-02-15 | Ciba Geigy Ag | |
| US4101541A (en) | 1973-12-21 | 1978-07-18 | Ciba-Geigy Corporation | 3-Cyano-1,2,4-thiadiazolyl-5-czo dyestuffs |
| FR2258841B1 (es) | 1974-01-29 | 1977-11-04 | Ugine Kuhlmann | |
| AT327605B (de) | 1974-05-06 | 1976-02-10 | Ciba Geigy Ag | Mittel zur hemmung des pflanzenwachstums |
| AU492126B2 (en) | 1974-05-14 | 1975-11-20 | Ciba-Geigy Ag | Nitropyrimidine derivatives |
| FR2306697A1 (fr) | 1975-04-10 | 1976-11-05 | Sogeras | Nouvelles pyrimidines utilisables comme medicaments antidiabetiques et hypocholesterolemiants |
| DE2731264A1 (de) | 1977-07-11 | 1979-02-01 | Boehringer Mannheim Gmbh | Neue 1-acyl-2-cyanaziridine, verfahren zu deren herstellung und diese verbindungen enthaltende pharmazeutische zubereitungen |
| JPS6038696B2 (ja) | 1977-12-09 | 1985-09-02 | コニカ株式会社 | ハロゲン化銀カラ−写真感光材料 |
| US4242507A (en) | 1978-02-23 | 1980-12-30 | Fujisawa Pharmaceutical Co., Ltd. | Sulfonic acid esters |
| DE2831580C2 (de) * | 1978-07-18 | 1980-09-18 | Boehringer Mannheim Gmbh, 6800 Mannheim | Verfahren und Reagens zur Bestimmung von Glycerin |
| DE2831850A1 (de) | 1978-07-20 | 1980-02-07 | Basf Ag | N-arylsulfonylpyrrole, ihre herstellung und diese enthaltende therapeutische mittel |
| DE2906603A1 (de) | 1979-02-21 | 1980-09-04 | Boehringer Mannheim Gmbh | N-substituierte aziridin-2-carbonsaeurederivate, verfahren zu deren herstellung sowie diese substanzen enthaltende arzneimittel |
| DOP1981004033A (es) | 1980-12-23 | 1990-12-29 | Ciba Geigy Ag | Procedimiento para proteger plantas de cultivo de la accion fitotoxica de herbicidas. |
| DE3334455A1 (de) | 1983-03-04 | 1984-09-06 | Bayer Ag, 5090 Leverkusen | Guanidin - derivate |
| ZA848275B (en) | 1983-12-28 | 1985-08-28 | Degussa | New piridine-2-ethers or pyridine-2-thioethers having a nitrogen-containing cycloaliphatic ring |
| DE3406329A1 (de) | 1984-02-22 | 1985-08-22 | Merck Patent Gmbh, 6100 Darmstadt | Pyridone |
| PH22302A (en) | 1985-02-11 | 1988-07-22 | Fujisawa Pharmaceutical Co | Piperidine compounds |
| IE860511L (en) | 1985-03-01 | 1986-09-01 | Alfa Farmaceutici Spa | "Benzoyl urea derivatives having anti-tumor activity" |
| DE3601196A1 (de) | 1986-01-17 | 1987-07-23 | Merck Patent Gmbh | 1,4-dihydropyridine |
| CA1340284C (en) | 1987-03-19 | 1998-12-22 | Zeneca Inc. | Herbicidal substituted cyclic diones |
| DE68926687T2 (de) | 1988-01-11 | 1997-03-06 | Fuji Photo Film Co Ltd | Verfahren zur Erzeugung von extrem hochkontrastreichen negativen Bildern |
| CA2070978A1 (en) | 1991-06-11 | 1992-12-12 | William J. Greenlee | Cyclic renin inhibitors |
| EP0556889A1 (en) | 1992-02-18 | 1993-08-25 | Duphar International Research B.V | Method of preparing aryl(homo)piperazines |
| TW237456B (es) | 1992-04-09 | 1995-01-01 | Ciba Geigy | |
| DE4241632A1 (de) | 1992-12-10 | 1994-06-16 | Thomae Gmbh Dr K | Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| GB9400889D0 (en) | 1994-01-18 | 1994-03-16 | Sandoz Ltd | Novel compounds |
| TW530047B (en) | 1994-06-08 | 2003-05-01 | Pfizer | Corticotropin releasing factor antagonists |
| CN1118454C (zh) | 1994-09-09 | 2003-08-20 | 日本新药株式会社 | 杂环衍生物和医药 |
| DK0801059T3 (da) | 1994-11-29 | 2001-09-24 | Dainippon Pharmaceutical Co | Indolderivat |
| US5691364A (en) | 1995-03-10 | 1997-11-25 | Berlex Laboratories, Inc. | Benzamidine derivatives and their use as anti-coagulants |
| US6956047B1 (en) | 1995-06-06 | 2005-10-18 | Pfizer Inc. | Corticotropin releasing factor antagonists |
| US6403599B1 (en) | 1995-11-08 | 2002-06-11 | Pfizer Inc | Corticotropin releasing factor antagonists |
| ES2193266T3 (es) | 1995-10-26 | 2003-11-01 | Mitsubishi Pharma Corp | Compuestos de feniletanolamina, utiles como agonistas de beta3, procedimiento para su produccion e intermedios de su produccion. |
| US5849759A (en) | 1995-12-08 | 1998-12-15 | Berlex Laboratories, Inc. | Naphthyl-substituted benzimidazole derivatives as anti-coagulants |
| DE19602095A1 (de) | 1996-01-22 | 1997-07-24 | Bayer Ag | Halogenpyrimidine |
| US5948786A (en) | 1996-04-12 | 1999-09-07 | Sumitomo Pharmaceuticals Company, Limited | Piperidinylpyrimidine derivatives |
| AR008789A1 (es) | 1996-07-31 | 2000-02-23 | Bayer Corp | Piridinas y bifenilos substituidos |
| US6008234A (en) | 1996-09-12 | 1999-12-28 | Berlex Laboratories, Inc. | Benzamidine derivatives substituted by cyclic amino acid and cyclic hydroxy acid derivatives and their use as anti-coagulants |
| IL123232A0 (en) | 1997-02-11 | 1999-11-30 | Lilly Co Eli | Medicament for inhibiting glucose metabolism deterioration |
| DE19737723A1 (de) | 1997-08-14 | 1999-02-18 | Bayer Ag | Methoximinomethyloxadiazine |
| US6187777B1 (en) | 1998-02-06 | 2001-02-13 | Amgen Inc. | Compounds and methods which modulate feeding behavior and related diseases |
| JP2000038350A (ja) | 1998-05-18 | 2000-02-08 | Yoshitomi Pharmaceut Ind Ltd | 糖尿病治療薬 |
| US6239126B1 (en) | 1998-12-17 | 2001-05-29 | American Home Products Corporation | Arylpiperidine and aryl-1,2,5,6-tetra-hydropyridine urea derivatives |
| US6267985B1 (en) | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
| EP1040831A3 (en) | 1999-04-02 | 2003-05-02 | Pfizer Products Inc. | Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death |
| AU5020400A (en) * | 1999-05-20 | 2000-12-12 | E.I. Du Pont De Nemours And Company | Heteroaryloxypyrimidine insecticides and acaricides |
| EP1074549B1 (en) | 1999-08-06 | 2003-11-19 | F. Hoffmann-La Roche Ag | Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors |
| JP2001089452A (ja) | 1999-09-22 | 2001-04-03 | Sankyo Co Ltd | ピリミジン誘導体 |
| US6414002B1 (en) | 1999-09-22 | 2002-07-02 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
| DE19962936A1 (de) | 1999-12-24 | 2001-06-28 | Bayer Ag | Neue beta-Aminosäureverbindungen als Integrinantagonisten |
| US6569879B2 (en) | 2000-02-18 | 2003-05-27 | Merck & Co., Inc. | Aryloxyacetic acids for diabetes and lipid disorders |
| ES2278755T3 (es) | 2000-05-18 | 2007-08-16 | Bayer Healthcare Ag | Regulacion del receptor acoplado a proteinas g de tipo dopamina humano. |
| US6620821B2 (en) | 2000-06-15 | 2003-09-16 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
| EP1294704A1 (en) | 2000-06-29 | 2003-03-26 | Abbott Laboratories | Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents |
| US20030224058A1 (en) | 2002-05-24 | 2003-12-04 | Elan Pharma International, Ltd. | Nanoparticulate fibrate formulations |
| US7276249B2 (en) | 2002-05-24 | 2007-10-02 | Elan Pharma International, Ltd. | Nanoparticulate fibrate formulations |
| AU2002248221B2 (en) | 2000-10-31 | 2006-08-17 | Merck & Co., Inc. | Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders |
| US20020058026A1 (en) | 2000-11-13 | 2002-05-16 | Milton Hammerly | HMG CoA reductase inhibitor medications combined wih CoEnzyme Q-10 |
| EP1340749A4 (en) | 2000-11-17 | 2007-09-05 | Takeda Pharmaceutical | isoxazole |
| US6545016B1 (en) | 2000-12-08 | 2003-04-08 | 3M Innovative Properties Company | Amide substituted imidazopyridines |
| US6525064B1 (en) | 2000-12-08 | 2003-02-25 | 3M Innovative Properties Company | Sulfonamido substituted imidazopyridines |
| US6545017B1 (en) | 2000-12-08 | 2003-04-08 | 3M Innovative Properties Company | Urea substituted imidazopyridines |
| NZ526532A (en) | 2001-01-26 | 2005-01-28 | Schering Corp | The use of substituted azetidinone compounds for the treatment of sitosterolemia |
| JP4510442B2 (ja) | 2001-06-26 | 2010-07-21 | ブリストル−マイヤーズ スクイブ カンパニー | ＴＮＦ−α発現のＮ−ヘテロ環インヒビター |
| GB2393825B (en) | 2001-08-02 | 2006-02-15 | Halliburton Energy Serv Inc | Adaptive acoustic transmitter controller apparatus and method |
| GB0229931D0 (en) | 2002-12-21 | 2003-01-29 | Astrazeneca Ab | Therapeutic agents |
| US20070225351A1 (en) | 2002-01-11 | 2007-09-27 | Lippa Arnold S | Methods and compositions for controlling body weight and appetite |
| US7057046B2 (en) | 2002-05-20 | 2006-06-06 | Bristol-Myers Squibb Company | Lactam glycogen phosphorylase inhibitors and method of use |
| EP1511467A1 (en) | 2002-06-10 | 2005-03-09 | Elan Pharma International Limited | Nanoparticulate polycosanol formulations and novel polycosanol combinations |
| GB0214254D0 (en) | 2002-06-20 | 2002-07-31 | Glaxo Group Ltd | Chemical compounds |
| SE0201976D0 (sv) | 2002-06-24 | 2002-06-24 | Astrazeneca Ab | Novel compounds |
| DK1531832T3 (da) | 2002-06-28 | 2009-07-27 | Glykos Finland Oy | Terapeutiske sammensætninger til anvendelse ved profylakse eller behandling af diarré |
| US20040053842A1 (en) | 2002-07-02 | 2004-03-18 | Pfizer Inc. | Methods of treatment with CETP inhibitors and antihypertensive agents |
| US7071210B2 (en) | 2002-07-02 | 2006-07-04 | Pfizer Inc. | CETP inhibitors in combination with antihypertensive agents and uses thereof |
| WO2004007468A1 (en) | 2002-07-15 | 2004-01-22 | Merck & Co., Inc. | Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes |
| JP4505327B2 (ja) | 2002-07-30 | 2010-07-21 | メルク・シャープ・エンド・ドーム・コーポレイション | 異常脂血症および他の脂質障害の治療用のＰＰＡＲα選択的化合物 |
| WO2004010936A2 (en) | 2002-07-30 | 2004-02-05 | Merck & Co., Inc. | Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders |
| US7144888B2 (en) | 2002-08-08 | 2006-12-05 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| WO2004017896A2 (en) | 2002-08-21 | 2004-03-04 | Merck & Co., Inc. | Combination therapy using a dual ppar alpha/gamma agonist and an angiotensin ii type i receptor antagonist |
| WO2004019869A2 (en) | 2002-08-29 | 2004-03-11 | Merck & Co., Inc. | Indoles having anti-diabetic activity |
| NZ538031A (en) | 2002-08-29 | 2007-10-26 | Merck & Co Inc | Indoles having anti-diabetic activity |
| WO2004033431A2 (en) | 2002-10-04 | 2004-04-22 | Arena Pharmaceuticals, Inc. | Hydroxypyrazoles for use against metabolic-related disorders |
| WO2004033710A2 (en) | 2002-10-09 | 2004-04-22 | Genaissance Pharmaceuticals, Inc. | Itgb3 gene haplotypes and atorvastatin dose effects on hdl cholesterol |
| JP2006507302A (ja) * | 2002-10-30 | 2006-03-02 | メルク エンド カムパニー インコーポレーテッド | キナーゼ阻害剤 |
| US7098235B2 (en) | 2002-11-14 | 2006-08-29 | Bristol-Myers Squibb Co. | Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds |
| US20040110241A1 (en) | 2002-12-06 | 2004-06-10 | Segal Mark S. | Materials and methods for monitoring vascular endothelial function |
| AU2003299791A1 (en) | 2002-12-20 | 2004-07-22 | Bayer Pharmaceuticals Corporation | Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity |
| CA2510793A1 (en) | 2002-12-20 | 2004-07-15 | Bayer Pharmaceuticals Corporation | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation |
| JO2397B1 (en) | 2002-12-20 | 2007-06-17 | ميرك شارب اند دوم كوربوريشن | Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors |
| BRPI0406761A (pt) | 2003-01-14 | 2005-12-20 | Arena Pharm Inc | Derivados de arila e heteroarila 1,2,3-trissubstituìdos como moduladores do metabolismo e a profilaxia e tratamento de distúrbios relacionados a estes tais como diabetes e hiper-glicemia |
| WO2004066963A2 (en) | 2003-01-17 | 2004-08-12 | Merck & Co., Inc. | N-cyclohexylaminocarbonyl benzenesulfonamide derivatives |
| PL378295A1 (pl) * | 2003-02-24 | 2006-03-20 | Arena Pharmaceuticals, Inc. | Podstawione pochodne arylowe i heteroarylowe jako modulatory metabolizmu glukozy oraz profilaktyka i leczenie zaburzeń tego metabolizmu |
| JP2004269468A (ja) | 2003-03-12 | 2004-09-30 | Yamanouchi Pharmaceut Co Ltd | ピリミジン誘導体又はその塩 |
| JP2004269469A (ja) | 2003-03-12 | 2004-09-30 | Yamanouchi Pharmaceut Co Ltd | ピリミジン誘導体又はその塩 |
| EP1622872A1 (en) | 2003-03-28 | 2006-02-08 | Pfizer Products Inc. | 1,2,4-substituerte 1,2,3,4-tetrahydro-and 1,2 dihydro-quinoline and 1,2,3,4-tetrahydro-quinoxaline derivatives as cetp inhibitors for the treatment of atherosclerosis and obesity |
| TWI393560B (zh) | 2003-05-02 | 2013-04-21 | Japan Tobacco Inc | 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合 |
| DK1475094T3 (da) | 2003-05-06 | 2010-11-22 | Univ Palackeho | Pyrazolo[4,3-d]pyrimidiner, fremgangsmåde til deres fremstilling samt deres anvendelse |
| US7083933B1 (en) | 2003-05-09 | 2006-08-01 | Prosidion Limited | Methods for identification of modulators of OSGPR116 activity |
| US20060160834A1 (en) | 2003-06-06 | 2006-07-20 | Fong Tung M | Combination therapy for the treatment of hypertension |
| EP1635832A2 (en) | 2003-06-06 | 2006-03-22 | Merck & Co., Inc. | Combination therapy for the treatment of diabetes |
| AR045047A1 (es) * | 2003-07-11 | 2005-10-12 | Arena Pharm Inc | Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos |
| RS20060018A (en) | 2003-07-14 | 2007-12-31 | Arena Pharmaceuticals Inc., | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
| FI116461B (fi) * | 2004-03-18 | 2005-11-30 | Kone Corp | Menetelmä hissin asentamiseksi ja hissin toimituskokonaisuus |
| CN1997640A (zh) | 2004-06-04 | 2007-07-11 | 艾尼纳制药公司 | 作为代谢调节剂的经取代芳基和杂芳基衍生物及其相关病症的预防和治疗 |
| MX2007003330A (es) | 2004-09-20 | 2007-06-05 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como agentes terapeuticos. |
| CA2582447C (en) | 2004-10-01 | 2012-04-17 | Merck & Co., Inc. | Aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| CN101084018B (zh) | 2004-11-03 | 2013-12-18 | 艾尼纳制药公司 | 用于治疗胰岛素相关病症的gpr41和其调节剂 |
| DOP2006000010A (es) * | 2005-01-10 | 2006-07-31 | Arena Pharm Inc | Procedimiento para preparar eteres aromáticos |
| MY148521A (en) * | 2005-01-10 | 2013-04-30 | Arena Pharm Inc | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto |
| DOP2006000008A (es) | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
| EP1838703A2 (en) | 2005-01-19 | 2007-10-03 | Neurogen Corporation | Heteroaryl substituted piperazinyl-pyridine analogues |
| ATE527253T1 (de) | 2005-07-01 | 2011-10-15 | Irm Llc | Pyrimidin-substituierte benzimidazolderivate als proteinkinasehemmer |
| TW200745055A (en) | 2005-09-23 | 2007-12-16 | Organon Nv | 4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives |
| UA96936C2 (uk) | 2005-12-29 | 2011-12-26 | Лексикон Фармасьютикалз, Инк. | Поліциклічні похідні амінокислот і їх застосування |
| BRPI0621226A2 (pt) | 2006-01-19 | 2012-07-10 | Orchid Reseach Lab Ltd | compostos heterociclos |
| PE20071221A1 (es) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
-
2006
- 2006-01-04 MY MYPI2010006219A patent/MY148521A/en unknown
- 2006-01-06 PE PE2006000046A patent/PE20060857A1/es not_active Application Discontinuation
- 2006-01-06 PE PE2009001073A patent/PE20091590A1/es not_active Application Discontinuation
- 2006-01-09 MX MX2007008402A patent/MX2007008402A/es active IP Right Grant
- 2006-01-09 PT PT06733644T patent/PT1732562E/pt unknown
- 2006-01-09 HN HN2006000969A patent/HN2006000969A/es unknown
- 2006-01-09 ES ES07023528T patent/ES2333824T4/es active Active
- 2006-01-09 CA CA002594466A patent/CA2594466A1/en not_active Abandoned
- 2006-01-09 AR ARP060100071A patent/AR054320A1/es not_active Application Discontinuation
- 2006-01-09 US US11/327,896 patent/US20060155128A1/en not_active Abandoned
- 2006-01-09 RS RSP-2008/0068A patent/RS50540B/sr unknown
- 2006-01-09 CN CN201010617617XA patent/CN102125555A/zh active Pending
- 2006-01-09 UA UAA200709148A patent/UA89812C2/ru unknown
- 2006-01-09 DK DK06733644T patent/DK1732562T3/da active
- 2006-01-09 SI SI200630025T patent/SI1732562T1/sl unknown
- 2006-01-09 NZ NZ556220A patent/NZ556220A/en not_active IP Right Cessation
- 2006-01-09 KR KR1020077018314A patent/KR20070098907A/ko not_active Application Discontinuation
- 2006-01-09 CN CNA2006800044893A patent/CN101115740A/zh active Pending
- 2006-01-09 EP EP06733644A patent/EP1732562B1/en active Active
- 2006-01-09 EA EA200701471A patent/EA015714B1/ru not_active IP Right Cessation
- 2006-01-09 PL PL06733644T patent/PL1732562T3/pl unknown
- 2006-01-09 AU AU2006211583A patent/AU2006211583C1/en not_active Ceased
- 2006-01-09 AT AT06733644T patent/ATE381558T1/de active
- 2006-01-09 DE DE602006009946T patent/DE602006009946D1/de active Active
- 2006-01-09 EP EP07023528A patent/EP1911756B9/en active Active
- 2006-01-09 WO PCT/US2006/000567 patent/WO2006083491A2/en active Application Filing
- 2006-01-09 PL PL07023528T patent/PL1911756T3/pl unknown
- 2006-01-09 PT PT07023528T patent/PT1911756E/pt unknown
- 2006-01-09 ES ES06733644T patent/ES2299167T4/es active Active
- 2006-01-09 SG SG201000207-9A patent/SG158875A1/en unknown
- 2006-01-09 JP JP2007550520A patent/JP2008526882A/ja active Pending
- 2006-01-09 DE DE602006000339T patent/DE602006000339T2/de active Active
- 2006-01-09 SI SI200630527T patent/SI1911756T1/sl unknown
- 2006-01-09 GT GT200600006A patent/GT200600006A/es unknown
- 2006-01-09 RS RSP-2009/0523A patent/RS51007B/sr unknown
- 2006-01-09 DK DK07023528.8T patent/DK1911756T3/da active
- 2006-01-09 AT AT07023528T patent/ATE446293T1/de active
- 2006-01-09 BR BRPI0606704-2A patent/BRPI0606704A/pt not_active IP Right Cessation
- 2006-01-09 TW TW095100772A patent/TW200637845A/zh unknown
- 2006-01-09 GE GEAP200611119A patent/GEP20094828B/en unknown
- 2006-07-06 US US11/482,777 patent/US8362248B2/en active Active
- 2006-11-20 US US11/601,927 patent/US20070078150A1/en not_active Abandoned
-
2007
- 2007-02-16 HK HK07101889A patent/HK1094542A1/xx not_active IP Right Cessation
- 2007-07-02 IL IL184363A patent/IL184363A0/en unknown
- 2007-07-03 CR CR9225A patent/CR9225A/es not_active Application Discontinuation
- 2007-07-04 ZA ZA200705471A patent/ZA200705471B/en unknown
- 2007-07-04 NI NI200700169A patent/NI200700169A/es unknown
- 2007-07-20 NO NO20073806A patent/NO20073806L/no not_active Application Discontinuation
-
2008
- 2008-02-27 CY CY20081100225T patent/CY1107215T1/el unknown
- 2008-03-12 HR HR20080113T patent/HRP20080113T3/xx unknown
- 2008-07-10 HK HK08107588.5A patent/HK1112241A1/xx not_active IP Right Cessation
-
2009
- 2009-12-31 CY CY20091101355T patent/CY1109696T1/el unknown
-
2010
- 2010-01-07 HR HR20100008T patent/HRP20100008T1/hr unknown
- 2010-03-05 HN HN2010000430A patent/HN2010000430A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR054320A1 (es) | Derivados de piridinilo y pirimidinilo sustituidos como moduladores del metabolismo y para tratar trastornos metabolicos. composiciones farmaceuticas | |
| PE20091005A1 (es) | N-(2-(hetaril)aril)arilsulfonamidas y n-(2-(hetaril)hetaril)arilsulfonamidas | |
| PE20191304A1 (es) | Modulador del regulador de conductancia de transmembrana de fibrosis quistica, composiciones farmaceuticas, metodos de tratamiento y proceso para producir el modulador | |
| PE20190336A1 (es) | Nuevos derivados de amonio, un proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| AR078408A1 (es) | Derivados de indol como moduladores de los crac | |
| AR066669A1 (es) | Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas. | |
| AR054799A1 (es) | Derivados de oxindol | |
| PE20141404A1 (es) | Derivados de tieno[3,2-d]pirimidina que tienen actividad inhibidora por las quinasas de las proteinas | |
| AR053774A1 (es) | Derivados de sulfonilbencimidazol. composiciones farmaceuticas. | |
| AR039540A1 (es) | Compuestos microbicidas con contenido de pirimidina o triazina | |
| PE20151601A1 (es) | Compuestos novedosos de pirimidina y piridina y su uso | |
| AR078163A1 (es) | Utilizacion de aminodihidrotiazinas para el tratamiento o prevencion de la diabetes | |
| NO20080391L (no) | Pyrazolbaserte LXR modulatorer | |
| AR041566A1 (es) | Derivados de indol utiles para el tratamiento de enfermedades | |
| AR076460A1 (es) | Antagonistas del receptor cxcr3 | |
| AR055959A1 (es) | Derivados espiro para la modulacion de actividad de crth2 | |
| AR058703A1 (es) | Triazolopiridazinas inhibidoras de tirosinquinasas, metodo de preparacion, composiciones farmaceuticas que las contienen y usos terapeuticos en el tratamiento del cancer | |
| PE20061150A1 (es) | Derivados de n-(n-sulfonilaminoarilmetil)ciclopropanocarboxamida sustituidos como antagonistas del receptor vainilloide tipo 1 (vdr1) | |
| PE20161443A1 (es) | Compuestos | |
| CR9459A (es) | Derivados benzodioxano y benzodioxolano y usos de los mismos | |
| PE20190504A1 (es) | Moduladores del receptor nmda espiro-lactam y uso de los mismos | |
| AR088029A1 (es) | Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central | |
| AR076550A1 (es) | Inhibidores de la janus tirosina kinasa (jak) | |
| PE20060776A1 (es) | Mimeticos de glucocorticoides, metodos para prepararlos y composiciones farmaceuticas | |
| AR065280A1 (es) | Agentes antiparasitarios |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |